發(fā)布時(shí)間：2018-05-18 17:47

  本文選題：垂體腺瘤 + 白細(xì)胞介素-6��； 參考：《山東大學(xué)》2016年博士論文

【摘要】：垂體是重要的內(nèi)分泌器官,通過(guò)分泌幾個(gè)重要的激素:催乳素(PRL),生長(zhǎng)激素(GH),促腎上腺皮質(zhì)激素(ACTH),促甲狀腺激素(TSH)等,在機(jī)體中發(fā)揮著至關(guān)重要的作用。垂體前葉通過(guò)調(diào)節(jié)靶腺激素分泌,參與組織器官的正常發(fā)育和生長(zhǎng)。垂體的異常嚴(yán)重?cái)_亂機(jī)體的代謝平衡,不同的器官會(huì)有不同程度的異常表現(xiàn)。垂體腺瘤是一種生長(zhǎng)在垂體前葉的特殊顱內(nèi)腫瘤,它不只具有一般腫瘤的特征還具有導(dǎo)致內(nèi)分泌紊亂的特點(diǎn)。垂體腺瘤大約占到腦腫瘤的10～20%,為多見(jiàn)的單克隆抗體起源腫瘤,在顱內(nèi)腫瘤中發(fā)病率接近腦膜瘤,排在膠質(zhì)瘤和腦膜瘤后面居第三位。大部分的垂體腺瘤為良性,只有小部分具有侵襲性,其中0.1～0.2%最終癌變,垂體腺癌的惡性程度與其預(yù)后密切相關(guān)。垂體腺瘤分為功能性腺瘤和非功能性腺瘤兩類(lèi),其臨床表現(xiàn)有包括占位效應(yīng)和內(nèi)分泌損害兩方面。非功能性腺瘤多于功能性腺瘤,在功能性腺瘤當(dāng)中,發(fā)病率最高為泌乳素腺瘤(PRL型),其下依次為生長(zhǎng)激素腺瘤(GH型)、促腎上腺皮質(zhì)激素腺瘤(ACTH型)、促卵泡和黃體生成素腺瘤(FSHLH)。功能性腺瘤的臨床癥狀主要由激素分泌紊亂導(dǎo)致的。兩類(lèi)腺瘤在生長(zhǎng)增大到一定程度時(shí)均可引起相應(yīng)的占位效應(yīng)。垂體腺瘤由一系列的垂體關(guān)鍵基因突變引起,這些基因包括蛋白激酶C(PKC)、p16、GADD45γ等。由于垂體腺瘤臨床表現(xiàn)的變異性和腫瘤的生長(zhǎng)不可預(yù)測(cè)性,引發(fā)了眾多研究者的的持續(xù)關(guān)注。以往的研究表明,垂體腺瘤可以從不同的角度對(duì)身體的發(fā)育和生長(zhǎng)產(chǎn)生負(fù)面的影響。垂體腺瘤引起的過(guò)量激素分泌會(huì)產(chǎn)生一系列代謝紊亂及臟器損傷。另一方面,由于腫瘤的壓迫,引起其他激素分泌的降低,會(huì)導(dǎo)致靶腺功能的下降。目前,對(duì)垂體腺瘤的化療及手術(shù)治療的研究已經(jīng)有大量的報(bào)道。已有的分子生物學(xué)研究表明,某些調(diào)控因子的基因和蛋白表達(dá)在垂體腺瘤中起著至關(guān)重要的作用。研究發(fā)現(xiàn)p53對(duì)垂體腺瘤的發(fā)生有著抑制作用,這種抑制作用可以被多形性腺瘤基因(pleomorphic adenoma gene-like 1,PLAGL1)與 RPRM,P21及佛波醇12肉豆蔻酸13醋酸酯誘導(dǎo)蛋白(phorbol-12-myristate-13-acetate-induced Protein 1,PMAIP1)的聯(lián)合作用所破壞。眾所周知GADD45β的過(guò)度表達(dá)可以通過(guò)激活細(xì)胞凋亡抑制因子抑制腫瘤的生長(zhǎng),這表明Gadd45β可能對(duì)垂體腺瘤也有潛在的抑制作用。垂體腺瘤可導(dǎo)致多種基因表達(dá)水平的升高或下降,其中大部分的變化也顯示對(duì)腫瘤發(fā)生的調(diào)控作用。雖然一些研究報(bào)告涉及到了垂體腺瘤對(duì)潛在靶基因的影響,到目前為止仍沒(méi)有滿意的解決方法系統(tǒng)性的通過(guò)對(duì)高通量數(shù)據(jù)分析的方法,對(duì)基因表達(dá)庫(kù)進(jìn)行研究以分析垂體腺瘤引起的基因和蛋白表達(dá)差異。本研究旨在通過(guò)基因表達(dá)譜分析將垂體腺瘤與正常垂體對(duì)照研究,以探討相關(guān)基因表達(dá)的類(lèi)型和變化。之后,通過(guò)建立蛋白質(zhì)相互作用(PPI)的差異表達(dá)基因網(wǎng)絡(luò)(DEGs),分析了垂體腺瘤差異性表達(dá)基因的影響以及不同的差異性蛋白質(zhì)之間的相互作用。研究的目的是通過(guò)在正常垂體及垂體腺瘤篩選差異表達(dá)基因及其蛋白產(chǎn)物,分析它們之間的相互作用,以研究垂體腺瘤的發(fā)病機(jī)理。通過(guò)搜集公共功能基因組學(xué)數(shù)據(jù)存儲(chǔ)庫(kù)(public functional genomics data repository)的基因表達(dá)譜(gene expression profiling),篩選出正常垂體及垂體腺瘤之間的差異表達(dá)基因(differential expressed genes,DEGs)。基因表達(dá)譜數(shù)據(jù)集GSE26966下載于功能性基因組數(shù)據(jù)庫(kù)GEO。在納入研究的23個(gè)樣品中,9個(gè)樣本取自正常垂體及14個(gè)樣本取自垂體腺瘤。所有探針集的注釋信息由Afffymetrix 人類(lèi)基因組 u133a2.0 陣列(Affmetrix Human Genome U133 Plus 2.0 Array)提供。在數(shù)據(jù)處理和差異表達(dá)分析時(shí),把CEL文件中探針?biāo)降臄?shù)據(jù)通過(guò)affy包系統(tǒng)的穩(wěn)健多元陣列平均函數(shù)(robust multi-array average,RMA)轉(zhuǎn)換成探針表達(dá)式值矩陣,并通過(guò)該數(shù)據(jù)集的芯片平臺(tái)R/Bioconductor注解包將編碼轉(zhuǎn)變?yōu)榛蛎Q(chēng)。由于一個(gè)基因有許多相應(yīng)的探針,最終將所有探針的表達(dá)式值的平均值通過(guò)計(jì)算(歸一化)對(duì)應(yīng)同一個(gè)基因的表達(dá)值。垂體腺瘤和正常垂體對(duì)比的差異表達(dá)基因(DEGs)通過(guò)R軟件limma包的貝葉斯線性模型識(shí)別,只有 log fold change(LFC)值1.5 和錯(cuò)誤發(fā)現(xiàn)率(false discovery rate,FDR)為校正的P0.05的基因才被選擇為差異表達(dá)基因(DEGs)。為了確保篩選的差異表達(dá)基因(DEGs)可以很好的體現(xiàn)樣本特征,本研究對(duì)差異表達(dá)基因(DEGs)進(jìn)行了聚類(lèi)分析并且繪制了聚類(lèi)圖。上調(diào)和下調(diào)的差異性表達(dá)基因功能則是通過(guò)對(duì)基因本體(gene ontology GO)的功能富集分析進(jìn)行進(jìn)一步的研究。之后,基因序列被映射到數(shù)據(jù)庫(kù),構(gòu)建成上調(diào)和下調(diào)的差異性表達(dá)基因的蛋白質(zhì)相互作用(protein-protein interactionPPI)網(wǎng)絡(luò)。研究發(fā)現(xiàn)下調(diào)差異表達(dá)基因(DEGs)的PPI網(wǎng)絡(luò)表現(xiàn)出相對(duì)集中的特點(diǎn),網(wǎng)絡(luò)中一些節(jié)點(diǎn)蛋白如EGR1,STAT3,JUNB和FOS都是癌癥中常見(jiàn)的轉(zhuǎn)錄因子。相對(duì)的,上調(diào)差異表達(dá)基因(DEGs)的PPI網(wǎng)絡(luò)表現(xiàn)出稀疏的狀態(tài)。通過(guò)這兩個(gè)PPI網(wǎng)絡(luò)之間的比較,證明下調(diào)基因在垂體腺瘤中起著主要作用。最后,對(duì)下調(diào)的差異表達(dá)基因的蛋白質(zhì)相互作用(PPI)網(wǎng)絡(luò)的功能模塊進(jìn)行分析。本研究在正常垂體和垂體腺瘤樣本間一共篩選出211個(gè)上調(diào)和413個(gè)下調(diào)差異表達(dá)基因。通過(guò)GO富集分析PPI網(wǎng)絡(luò)建立,發(fā)現(xiàn)下調(diào)的差異表達(dá)基因與免疫反應(yīng)、激素調(diào)節(jié)和細(xì)胞增殖等功能相關(guān)。上調(diào)的差異性表達(dá)基因與陽(yáng)離子轉(zhuǎn)運(yùn)功能相關(guān)。從下調(diào)的差異表達(dá)基因的PPI網(wǎng)絡(luò)獲得五個(gè)模塊。其中四個(gè)具有明顯的生物學(xué)作用,其中的轉(zhuǎn)錄因子,如IL-6,STAT3,BCL6,EGR1,POU1F1,JunB和Fos是這些功能模塊的核心節(jié)點(diǎn)。本研究通過(guò)對(duì)正常垂體和垂體腺瘤基因表達(dá)譜和PPI網(wǎng)絡(luò)的篩選成功地找到差異表達(dá)基因及其相關(guān)的蛋白質(zhì)。結(jié)果表明,激素和免疫相關(guān)基因的低表達(dá)促進(jìn)垂體腺瘤的發(fā)生。低表達(dá)的IL6和STAT3在垂體腺瘤的免疫異常中扮演了關(guān)鍵的角色。同時(shí),POU1F1低表達(dá)導(dǎo)致垂體激素分泌的減少,是垂體腺瘤的重要誘因。垂體腺瘤理想治療目標(biāo)為調(diào)整患者激素水平至正常范圍,消除瘤體對(duì)周?chē)M織的壓迫,緩解瘤體在顱內(nèi)誘發(fā)的不良癥狀及體征等。目前臨床上垂體腺瘤常用的治療方案為手術(shù)切除和放射治療,但二者在實(shí)際臨床應(yīng)用中均存在一定的局限性。手術(shù)切除作為垂體腺瘤臨床治療的首選方案,雖然能有效緩解瘤體對(duì)周?chē)M織的壓迫,下調(diào)患者激素水平,但若瘤體切除不完全或腫瘤已出現(xiàn)周?chē)M織侵犯,可導(dǎo)致手術(shù)的風(fēng)險(xiǎn)性增加,誘發(fā)諸多并發(fā)癥并易發(fā)生術(shù)后復(fù)發(fā)。放射治療主要用于術(shù)后復(fù)發(fā)、殘留及不耐受或拒絕手術(shù)患者,作為垂體腺瘤治療的二線方案,放射治療可抑制腫瘤的生長(zhǎng),恢復(fù)患者激素分泌水平,但治療周期較長(zhǎng),且有研究顯示放射治療可誘發(fā)垂體功能減退,損傷顱內(nèi)神經(jīng)細(xì)胞,嚴(yán)重時(shí)還可導(dǎo)致惡性腫瘤的發(fā)生。因此結(jié)合患者的臨床病理特征,權(quán)衡利弊選擇合理的治療方案對(duì)垂體腺瘤患者預(yù)后改善有著重要意義。研究證實(shí)腫瘤的發(fā)生發(fā)展是一個(gè)復(fù)雜、多步驟的連續(xù)過(guò)程,免疫逃逸作為腫瘤惡化進(jìn)展的關(guān)鍵,目前普遍認(rèn)為其與腫瘤周?chē)h(huán)境的改變有關(guān)[1]。正常狀態(tài)下,免疫系統(tǒng)的淋巴細(xì)胞可通過(guò)抗原識(shí)別完成對(duì)惡變細(xì)胞和自體細(xì)胞的有效區(qū)分,但在腫瘤細(xì)胞中,它一方面可通過(guò)降低或沉默自身免疫原性來(lái)躲避免疫系統(tǒng)的抗原識(shí)別;另一方面它可激活免疫抑制細(xì)胞如調(diào)節(jié)性T細(xì)胞(Treg)和調(diào)節(jié)性B細(xì)胞(Breg),誘導(dǎo)分泌免疫抑制細(xì)胞因子如TGF-β和IL-10[2],在腫瘤病灶組織周?chē)纬擅庖咭种凭W(wǎng)絡(luò)最終實(shí)現(xiàn)免疫逃逸。對(duì)Treg細(xì)胞在腫瘤發(fā)生發(fā)展中的作用國(guó)內(nèi)外學(xué)者已展開(kāi)的大量的研究,Breg細(xì)胞作為另一大類(lèi)具有特殊免疫抑制功能細(xì)胞,以往研究多集中在自身免疫性疾病、移植免疫耐受、感染與炎癥反應(yīng)等方面,但伴隨研究深入,發(fā)現(xiàn)Breg細(xì)胞也參與促腫瘤的生長(zhǎng)及轉(zhuǎn)移[3,4]。包括皮膚良性腫瘤的發(fā)生、抑制T淋巴細(xì)胞的抗腫瘤效應(yīng)、抑制肝癌細(xì)胞的凋亡、增強(qiáng)肝癌細(xì)胞的增殖和遷移活性。臨床研究也證實(shí)在卵巢癌、胃癌、肺癌、胰腺癌、乳腺癌等惡性實(shí)體瘤中可見(jiàn)Bregs細(xì)胞的浸潤(rùn)并與腫瘤微環(huán)境的免疫抑制及腫瘤的惡性侵襲密切相關(guān)。鑒于Bregs在腫瘤進(jìn)展中的重要作用,針對(duì)Bregs的靶向藥物研究成為目前的關(guān)注熱點(diǎn),尤其是腫瘤局部浸潤(rùn)Bregs,通過(guò)直接干預(yù)Bregs活化數(shù)量消除其負(fù)性調(diào)控,或間接抑制Bregs分泌的細(xì)胞因子恢復(fù)免疫監(jiān)視功能發(fā)揮抗腫瘤效應(yīng),成為目前腫瘤治療研究的新型靶向。B10細(xì)胞作為Bregs的亞型,研究顯示這一類(lèi)含量稀少表型特殊的B細(xì)胞在腫瘤逃逸過(guò)程中有著重要作用,包括參與CLL免疫抑制調(diào)控[11]、胰腺癌的進(jìn)展過(guò)程[12]。研究證實(shí)放射治療過(guò)程中腫瘤細(xì)胞的凋亡可導(dǎo)致腫瘤抗原的釋放進(jìn)而激活機(jī)體的先天免疫信號(hào)[13],并伴隨腫瘤微環(huán)境免疫抑制的減弱[14]。這也提示我們?cè)诖贵w腺瘤反射治療過(guò)程中,是否同樣存在B10細(xì)胞的變化,因此圍繞垂體腺瘤放療患者組織內(nèi)B10細(xì)胞變化我們展開(kāi)了相關(guān)研究,收集復(fù)發(fā)垂體腺瘤患者48例,23例術(shù)前接受放射治療,25例未接受治療,患者經(jīng)手術(shù)摘除垂體腺瘤后,通過(guò)檢測(cè)垂體腺瘤患者組織CD19+CD1d+CD5+和B10細(xì)胞亞群比例,測(cè)定垂體腺瘤患者組織miR-98和HDAC1 mRNA表達(dá),明確放射治療過(guò)程中垂體腺瘤患者組織B10細(xì)胞變化特點(diǎn)。研究發(fā)現(xiàn)放射治療可下調(diào)垂體腺瘤患者組織中B10細(xì)胞及其亞群CD19+CD1d+CD5+和CD19+CD24+CD38+數(shù)量及分布頻率;放射治療垂體腺瘤患者組織中miR-98 mRNA表達(dá)顯著上調(diào),提示放射治療可促進(jìn)miR-98表達(dá),miR-98表達(dá)上調(diào)可抑制IL-10轉(zhuǎn)錄,進(jìn)而影響B(tài)10細(xì)胞免疫抑制功能。
[Abstract]:The pituitary gland is an important endocrine organ, which plays a vital role in the body by secreting a few important hormones, such as PRL, GH, ACTH, and TSH. The anterior pituitary is involved in the normal development and growth of the tissues and organs by regulating the secretion of the target gland hormone. The pituitary adenoma is a special intracranial tumor that grows in the anterior pituitary. It is not only characteristic of the general tumor, but also has the characteristics of endocrine disorder. The pituitary adenoma accounts for about 10 to 20% of the brain tumor, which is a common monoclonal antibody. The incidence of tumor origin is close to meningioma in intracranial tumors and third in glioma and meningioma. Most pituitary adenomas are benign, only a small part is invasive, of which 0.1 to 0.2% are eventually cancerous, and the malignancy of pituitary adenocarcinoma is closely related to the prognosis. Pituitary adenomas are divided into functional adenomas and nonfunctional glands. There are two types of tumor, including two aspects of space occupying effect and endocrine damage. Nonfunctional adenomas are more than functional adenomas. Among functional adenomas, the highest incidence is prolactin adenoma (type PRL), which is followed by growth hormone adenoma (type GH), adrenocorticotropic hormone adenoma (ACTH type), follicle promoting and luteinizing adenoma (FSH LH. The clinical symptoms of functional adenomas are mainly caused by hormonal disorder. The two types of adenomas may cause the corresponding occupying effect when the growth is increased to a certain extent. Pituitary adenomas are caused by a series of mutations in the key pituitary genes, including protein kinase C (PKC), p16, GADD45 gamma, and so on. The unpredictability of the growth of the heterosexual and tumor growth has led to the continuous attention of many researchers. Previous studies have shown that pituitary adenomas can have a negative impact on the development and growth of the body from different angles. The excessive hormone secretion caused by pituitary adenomas may produce a series of metabolic disorders and organ damage. On the other hand, the swelling is due to swelling. The pressure of the tumor, causing the decrease of other hormone secretion, will lead to the decline of the function of the target gland. At present, there have been a lot of reports on the chemotherapy and surgical treatment of pituitary adenomas. Molecular biology studies have shown that the gene and protein expression of some regulatory factors play a vital role in pituitary adenomas. Research has found that p53 It has an inhibitory effect on the occurrence of pituitary adenomas, which can be destroyed by the combination of the pleomorphic adenoma gene-like 1, PLAGL1 and RPRM, P21 and the 12 myristic acid 13 acetate induced protein (phorbol-12-myristate-13-acetate-induced Protein 1, PMAIP1). Overexpression can inhibit tumor growth by activating the inhibitory factor of apoptosis, which suggests that Gadd45 beta may also have a potential inhibitory effect on pituitary adenomas. Pituitary adenomas may lead to a rise or decline in a variety of gene expression levels, and most of the changes also indicate the regulatory role of the tumor. The effect of pituitary adenoma on potential target genes has not been satisfactorily solved so far. The gene and protein expression differences caused by pituitary adenomas are analyzed by the method of high throughput data analysis to analyze the difference in gene and protein expression caused by pituitary adenomas. Normal pituitary control study to explore the types and changes of related gene expression. After that, the differential expression gene network (DEGs) of protein interaction (PPI) was established to analyze the influence of differentially expressed genes in pituitary adenomas and the interaction between different differential proteins. The purpose of this study was to pass through the normal pituitary and drooping. Body adenoma screening differentially expressed genes and their protein products to analyze the interaction between them in order to study the pathogenesis of pituitary adenomas. By collecting the gene expression profiles (gene expression profiling) of the public functional genomics data repository (gene expression profiling), the normal pituitary gland and the pituitary gland were screened. The differential expression gene (differential expressed genes, DEGs). The gene expression profile data set GSE26966 was downloaded from the functional genomic database GEO. in the 23 samples taken into the study. 9 samples were taken from the normal pituitary and 14 samples were taken from the pituitary adenoma. The annotation information of all the probe sets was derived from the Afffymetrix human genome u133a2. The.0 array (Affmetrix Human Genome U133 Plus 2 Array) is provided. In data processing and differential expression analysis, the probe level data in the CEL file is converted to the probe expression value matrix through the robust multivariate array average function of the Affy packet system (robust multi-array average,) and through the chip platform of the data set The uctor annotated packet transforms the encoding into a gene name. As a gene has a number of corresponding probes, the average value of the expression value of all probes is finally calculated (normalized) to correspond to the expression value of the same gene. The differential expression gene (DEGs) of the pituitary adenoma and the normal pituitary (DEGs) is used by the Bayesian linear model of the R software package. Identification, only the log fold change (LFC) value 1.5 and the error discovery rate (false discovery rate, FDR) are selected as the differentially expressed genes (DEGs). In order to ensure that the selected differentially expressed genes (DEGs) can well reflect the sample characteristics, the differentially expressed genes (DEGs) are cluster analysis and plotted in this study. The function of differentially expressed genes between up and down is further studied by the functional enrichment analysis of gene ontology GO. After that, the gene sequence is mapped to the database to construct the protein interaction (protein-protein interactionPPI) network of up and down differentially expressed genes (protein-protein interactionPPI). The study found that the PPI network that down regulated differentially expressed genes (DEGs) showed a relatively concentrated characteristic. Some of the nodes in the network, such as EGR1, STAT3, JUNB and FOS, were common transcription factors in cancer. Relative, the PPI network up regulating the differential expression gene (DEGs) showed a sparse state. By comparison of these two PPI networks Down regulated genes play a major role in pituitary adenomas. Finally, the functional modules of the protein interaction (PPI) network of down regulated differentially expressed genes were analyzed. In this study, 211 up-regulated and 413 down regulated differentially expressed genes were screened in normal pituitary and pituitary adenoma samples. The PPI network was established by GO enrichment analysis. The down regulated differentially expressed genes were related to the functions of the immune response, hormone regulation and cell proliferation. The up-regulated differentially expressed genes were related to the cation transport function. Five modules were obtained from the PPI network of down regulated differentially expressed genes. Four of them had obvious biological use, such as the transcription factors, such as IL-6, STAT3, BCL6, E. GR1, POU1F1, JunB and Fos are the core nodes of these functional modules. This study successfully found differentially expressed genes and related proteins by screening gene expression profiles and PPI networks of normal pituitary and pituitary adenomas. The results showed that the low expression of hormone and immune related genes promoted the occurrence of pituitary adenomas. Low expression of IL6 and STAT. 3 plays a key role in the immune abnormality of pituitary adenoma. At the same time, the low expression of POU1F1 leads to the decrease of pituitary hormone secretion. It is an important cause of pituitary adenoma. The ideal treatment of pituitary adenoma is to adjust the level of the hormone to the normal range, eliminate the oppression of the tumor body to the surrounding tissue and alleviate the adverse symptoms induced by the tumor in the intracranial. At present, surgical resection and radiotherapy are commonly used in the clinical treatment of pituitary adenomas, but there are some limitations in the actual clinical application of the two. Surgical excision is the first choice for clinical treatment of pituitary adenomas, although it can effectively alleviate the compression of the surrounding tissue and reduce the level of the hormone in the patient, but if the tumor is tumor An incomplete resection of the body or an invasion of the surrounding tissue may lead to an increase in the risk of surgery, a number of complications and postoperative recurrence. Radiation therapy is mainly used for postoperative recurrence, residual and intolerance or rejection of the operation, as a second line of pituitary adenoma treatment. Radiation therapy can inhibit the growth of the tumor and restore the patient. The level of hormone secretion is long, but the treatment cycle is longer, and there are studies showing that radiation therapy can induce hypophysis dysfunction and injury of intracranial nerve cells, and it can also lead to malignant tumor. Therefore, combining the clinicopathological features of the patients, choosing a reasonable treatment scheme to weigh the advantages and disadvantages is important to improve the prognosis of pituitary adenoma patients. Research confirms that the development of tumor is a complex, multi step process. Immune escape is the key to the progression of cancer. It is generally believed that it is related to the change of the microenvironment around the tumor, which is related to the normal state of [1].. The lymphocyte of the immune system can be used to complete the effective cells and autologous cells through the antigen recognition. But in tumor cells, it can avoid the antigen recognition of the immune system by reducing or silent autoimmunity, on the other hand, it activates the immunosuppressive cells such as regulatory T cells (Treg) and regulatory B cells (Breg), inducing secretory cytokines such as TGF- beta and IL-10[2], around the tumor tissue. The formation of immunosuppressive networks finally realizes immune escape. The role of Treg cells in the development of tumors has been extensively studied by domestic and foreign scholars. Breg cells have special immunosuppressive functions as another major class. Previous studies focused on autoimmune diseases, transplantation immune tolerance, infection and inflammation, and so on. However, with the further study, it is found that Breg cells also participate in the growth of tumor and the metastasis of [3,4]. including benign tumor of the skin, inhibit the anti-tumor effect of T lymphocyte, inhibit the apoptosis of hepatoma cells, enhance the proliferation and migration activity of the hepatoma cells. The clinical study also confirmed that the malignant tumor, gastric cancer, lung cancer, pancreatic cancer, and breast cancer are malignant. The infiltration of Bregs cells in solid tumors is closely related to the immunosuppression of the tumor microenvironment and the malignant invasion of the tumor. In view of the important role of Bregs in the progression of the tumor, the research on targeted drugs for Bregs has become the focus of attention, especially the local infiltration of Bregs in the tumor, and to eliminate the negative effects of the number of Bregs activated by direct intervention in the number of Bregs. The regulation, or the indirect inhibition of the cytokines secreted by Bregs to restore the immune surveillance function to play an antitumor effect, has become a new target.B10 cell for cancer therapy as a subtype of Bregs. The study shows that this kind of rare B cells with rare phenotypes have an important role in the process of tumor escape, including participation in the CLL immune suppression. [11], the progress of pancreatic cancer [12]. research confirms that the apoptosis of tumor cells in the course of radiation therapy can lead to the release of tumor antigen and then activate the organism's innate immune signal [13], and with the decrease of [14]. in the tumor microenvironment immunity inhibition, it also suggests that we also have B10 cells in the process of pituitary adenoma counter shoot treatment. The changes of B10 cells in the tissue of patients with pituitary adenoma were studied, 48 cases of recurrent pituitary adenomas were collected, 23 patients received radiotherapy before operation, 25 cases were untreated. After surgical removal of pituitary adenomas, the proportion of CD19+CD1d+CD5+ and B10 cell subgroups in the pituitary adenoma was detected by detecting the pituitary adenoma. The expression of miR-98 and HDAC1 mRNA in the tissue of pituitary adenoma was determined and the characteristics of B10 cell changes in the tissue of pituitary adenoma patients were determined. The study found that radiation therapy could reduce the number and frequency of B10 cells and their subgroups CD19+CD1d+CD5+ and CD19+CD24+CD38+ in the tissues of pituitary adenomas; radiation therapy for pituitary adenoma patients group. The expression of miR-98 mRNA was significantly up-regulated, suggesting that radiotherapy can promote the expression of miR-98. Up regulation of miR-98 can inhibit the transcription of IL-10 and further affect B10.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R736.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 柴青芬,王曉琪,黃其鎏,鄭衛(wèi)權(quán);底節(jié)區(qū)無(wú)功能嗜酸細(xì)胞性垂體腺瘤1例報(bào)告[J];第一軍醫(yī)大學(xué)學(xué)報(bào);2000年01期

2 任祖淵;努力提高垂體腺瘤的診斷和治療水平[J];中華神經(jīng)外科雜志;2000年03期

3 汪三合;垂體腺瘤誤診為慢性單純性青光眼1例原因淺析[J];山西臨床醫(yī)藥;2000年10期

4 金許洪,金晨宇,朱惠軍;垂體腺瘤術(shù)后的中西醫(yī)治療[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2000年23期

5 劉學(xué)鍵,李克雷,蘇傳富;垂體腺瘤33例誤診分析[J];職業(yè)與健康;2000年02期

6 魏新亭,羅世祺;垂體腺瘤p16基因啟動(dòng)子甲基化分析[J];河南實(shí)用神經(jīng)疾病雜志;2001年04期

7 閆志鈞,林志國(guó),沈紅,李慶國(guó),隋立森,浦松;垂體腺瘤的X刀治療[J];立體定向和功能性神經(jīng)外科雜志;2001年04期

8 趙明,劉偉國(guó),楊小鋒;老年人垂體腺瘤的診斷與治療[J];浙江創(chuàng)傷外科;2001年03期

9 馬增路;垂體腺瘤誤診55例分析[J];中國(guó)綜合臨床;2002年06期

10 竇萬(wàn)臣,馬超,王任直,任祖淵;復(fù)發(fā)性垂體腺瘤的診斷和治療[J];中華神經(jīng)外科雜志;2002年02期

相關(guān)會(huì)議論文 前10條

1 林志仁;程剛;;X線分次立體適形放療垂體腺瘤35例[A];中華醫(yī)學(xué)會(huì)放射腫瘤治療學(xué)分會(huì)六屆二次暨中國(guó)抗癌協(xié)會(huì)腫瘤放療專(zhuān)業(yè)委員會(huì)二屆二次學(xué)術(shù)會(huì)議論文集[C];2009年

2 魏宇佳;;老年人垂體腺瘤臨床特征及隨診分析[A];中華醫(yī)學(xué)會(huì)神經(jīng)外科學(xué)分會(huì)第九次學(xué)術(shù)會(huì)議論文匯編[C];2010年

3 王樹(shù)興;李學(xué)芝;紀(jì)宇明;田維東;彭龍峰;姜京超;楊軍;;老年人垂體腺瘤手術(shù)治療(附30例臨床分析)[A];中華醫(yī)學(xué)會(huì)神經(jīng)外科學(xué)分會(huì)第九次學(xué)術(shù)會(huì)議論文匯編[C];2010年

4 王任直;;規(guī)范化治療是提高垂體腺瘤診治水平的關(guān)鍵[A];中國(guó)醫(yī)師協(xié)會(huì)神經(jīng)外科醫(yī)師分會(huì)首屆全國(guó)代表大會(huì)論文匯編[C];2005年

5 潘紅日;周開(kāi)宇;金涌;王廣濤;;經(jīng)鼻蝶入路顯微手術(shù)治療垂體腺瘤[A];2005年浙江省神經(jīng)外科學(xué)術(shù)會(huì)議論文匯編[C];2005年

6 傅偉明;龔江標(biāo);李谷;鄭秀玨;楊小鋒;劉偉國(guó);;巨大垂體腺瘤分次手術(shù)治療探討[A];2007浙江省神經(jīng)外科學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2007年

7 牛煥江;王義榮;朱先理;楊樹(shù)旭;孫偉軍;臧國(guó)堯;李新偉;方兵;錢(qián)聰;甘海鵬;;微骨孔入路手術(shù)治療垂體腺瘤療效分析[A];2007浙江省神經(jīng)外科學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2007年

8 鄒杰;馮正國(guó);;垂體腺瘤的眼部改變和誤診分析[A];中國(guó)眼底病論壇·全國(guó)眼底病專(zhuān)題學(xué)術(shù)研討會(huì)論文匯編[C];2008年

9 曾梅芳;蔣翠萍;趙雪蘭;吳蔚;苗青;張瓊月;黃杉;何敏;張爍;楊葉虹;李士其;趙耀;葉紅英;李益明;;垂體腺瘤術(shù)后垂體前葉功能減退及替代治療情況研究[A];中華醫(yī)學(xué)會(huì)第十次全國(guó)內(nèi)分泌學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2011年

10 劉光耀;王寧;武玉剛;戰(zhàn)華;孟祥喜;趙世光;;白細(xì)胞介素-18在人類(lèi)垂體腺瘤組織中的表達(dá)及分布[A];2011中華醫(yī)學(xué)會(huì)神經(jīng)外科學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2011年

相關(guān)重要報(bào)紙文章 前10條

1 王任直;應(yīng)用循證醫(yī)學(xué) 診治垂體腺瘤[N];健康報(bào);2007年

2 劉橋斌 特約記者　 林夕夕;大多垂體腺瘤不需治療[N];健康時(shí)報(bào);2007年

3 健康時(shí)報(bào)特約記者 朱麗麗;突然閉經(jīng)排查垂體腺瘤[N];健康時(shí)報(bào);2007年

4 本報(bào)記者　 馬艷紅;規(guī)范治療垂體腺瘤任務(wù)迫切[N];中國(guó)醫(yī)藥報(bào);2006年

5 本報(bào)記者 鐘思思;垂體腺瘤 找出病源防誤診[N];保健時(shí)報(bào);2004年

6 ;腦垂體腺瘤表相在四肢軀干[N];北京日?qǐng)?bào);2006年

7 本報(bào)記者 李穎;身體變形 警惕垂體腺瘤[N];科技日?qǐng)?bào);2014年

8 高素英;垂體腺瘤高發(fā)不容忽視[N];中國(guó)醫(yī)藥報(bào);2014年

9 李士其;老年人垂體腺瘤與微創(chuàng)手術(shù)治療[N];中國(guó)中醫(yī)藥報(bào);2004年

10 記者 匡遠(yuǎn)深 通訊員 趙晶晶;內(nèi)鏡加盟“搞定”垂體腺瘤[N];健康報(bào);2014年

相關(guān)博士學(xué)位論文 前10條

1 徐藝文;5-羥甲基胞嘧啶在無(wú)功能垂體腺瘤中的變化及其調(diào)節(jié)機(jī)制研究[D];北京協(xié)和醫(yī)學(xué)院;2016年

2 孔令勝;GH型垂體腺瘤MRI、血內(nèi)分泌激素與激素免疫組化特點(diǎn)及其相互關(guān)系的研究[D];青島大學(xué);2016年

3 王珞;垂體促腎上腺皮質(zhì)激素腺瘤全基因組測(cè)序分析[D];浙江大學(xué);2015年

4 賈睿超;垂體腺瘤中NPY、miR-15a/miR-16和Bcl-2相關(guān)性研究[D];天津醫(yī)科大學(xué);2014年

5 王明光;PTEN和CIRP與垂體腺瘤侵襲性的相關(guān)性研究[D];山東大學(xué);2016年

6 王偉民;垂體腺瘤發(fā)病機(jī)理的基因表達(dá)譜分析及B10細(xì)胞在放療后垂體腺瘤組織中變化的研究[D];山東大學(xué);2016年

7 馬林;垂體腺瘤分子生物學(xué)特征和手術(shù)治療的研究[D];天津醫(yī)科大學(xué);2006年

8 陳來(lái)照;神經(jīng)肽Y及其受體在垂體腺瘤中的表達(dá)及意義[D];天津醫(yī)科大學(xué);2006年

9 夏學(xué)巍;過(guò)氧化物酶增殖物激活受體γ激動(dòng)劑治療垂體腺瘤的實(shí)驗(yàn)研究[D];中國(guó)協(xié)和醫(yī)科大學(xué);2005年

10 唐建建;骨橋蛋白與垂體腺瘤侵襲性的相關(guān)性研究[D];四川大學(xué);2006年

相關(guān)碩士學(xué)位論文 前10條

1 劉琦;基質(zhì)金屬蛋白酶和血管內(nèi)皮生長(zhǎng)因子表達(dá)與垂體腺瘤侵襲性關(guān)系的研究[D];蘇州大學(xué);2005年

2 姜海洋;垂體腺瘤術(shù)后低鈉血癥與血漿B型腦鈉肽水平的相關(guān)性研究[D];蘭州大學(xué);2015年

3 陶曉e，

本文編號(hào)：1906599